285 related articles for article (PubMed ID: 18473857)
1. Combinatorial application of nucleic acid-based agents targeting protein kinases for cancer treatment.
Spänkuch B; Strebhardt K
Curr Pharm Des; 2008; 14(11):1098-112. PubMed ID: 18473857
[TBL] [Abstract][Full Text] [Related]
2. Gene targets of antisense therapies in breast cancer.
Yang DC; Elliott RL; Head JF
Expert Opin Ther Targets; 2002 Jun; 6(3):375-85. PubMed ID: 12223074
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
Ziegler A; Luedke GH; Fabbro D; Altmann KH; Stahel RA; Zangemeister-Wittke U
J Natl Cancer Inst; 1997 Jul; 89(14):1027-36. PubMed ID: 9230884
[TBL] [Abstract][Full Text] [Related]
4. Nucleic acid modulation of gene expression: approaches for nucleic acid therapeutics against cancer.
Nakata Y; Kim TK; Shetzline S; Gewirtz AM
Crit Rev Eukaryot Gene Expr; 2005; 15(2):163-82. PubMed ID: 16022634
[TBL] [Abstract][Full Text] [Related]
5. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A.
Tortora G; Caputo R; Damiano V; Bianco R; Pepe S; Bianco AR; Jiang Z; Agrawal S; Ciardiello F
Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12586-91. PubMed ID: 9356493
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
[TBL] [Abstract][Full Text] [Related]
7. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
9. Biology and medicinal chemistry approaches towards various apoptosis inducers.
Vyas VK; Chintha C; Pandya MR
Anticancer Agents Med Chem; 2013 Mar; 13(3):433-55. PubMed ID: 22721391
[TBL] [Abstract][Full Text] [Related]
10. Locked nucleic acid holds promise in the treatment of cancer.
Frieden M; Ørum H
Curr Pharm Des; 2008; 14(11):1138-42. PubMed ID: 18473860
[TBL] [Abstract][Full Text] [Related]
11. Targeting different signaling pathways with antisense oligonucleotides combination for cancer therapy.
Leonetti C; Zupi G
Curr Pharm Des; 2007; 13(5):463-70. PubMed ID: 17348843
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
Sypniewski D; Bednarek I; Gałka S; Loch T; Błaszczyk D; Sołtysik D
Acta Pol Pharm; 2013; 70(1):87-97. PubMed ID: 23610963
[TBL] [Abstract][Full Text] [Related]
13. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
[TBL] [Abstract][Full Text] [Related]
14. Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies.
Taniguchi H; Suzuki Y; Imai K; Adachi Y
Cancer Sci; 2022 Sep; 113(9):2952-2961. PubMed ID: 35701833
[TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
16. RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions.
MacLeod AR; Crooke ST
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S43-S59. PubMed ID: 28921648
[TBL] [Abstract][Full Text] [Related]
17. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides: a new therapeutic approach.
Temsamani J; Guinot P
Biotechnol Appl Biochem; 1997 Oct; 26(2):65-71. PubMed ID: 9357101
[TBL] [Abstract][Full Text] [Related]
20. Capsaicinoids enhance chemosensitivity to chemotherapeutic drugs.
Friedman JR; Richbart SD; Merritt JC; Perry HE; Brown KC; Akers AT; Nolan NA; Stevenson CD; Hurley JD; Miles SL; Tirona MT; Valentovic MA; Dasgupta P
Adv Cancer Res; 2019; 144():263-298. PubMed ID: 31349900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
